China (Mainland)
Assessedsupplier
Tigecycline CAS NO.220620-09-7
- Min.Order: 1 Kilogram
- Payment Terms: L/C,T/T
- Product Details
Keywords
- 220620-09-7
- Tigecycline
- Tigecycline
Quick Details
- ProName: Tigecycline
- CasNo: 220620-09-7
- Molecular Formula: C29H39N5O8
- Appearance: solid
- Application: For Organic synthsis
- DeliveryTime: prompt
- PackAge: As per customer's
- Port: shagnhai
- ProductionCapacity: 10 Metric Ton/Month
- Purity: 98.0% Min
- Storage: Room temperature
- Transportation: To be shipped as non-hazardous chemica...
- LimitNum: 1 Kilogram
- Grade: Industrial Grade,Food Grade,Pharma Gra...
Superiority
| Tigecycline Basic information |
| Gansu ammonia acyl ring element class of antibiotics Indication Adverse reaction |
| Product Name: | Tigecycline |
| Synonyms: | 2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-9-[[[(1,1-DIMETHYLETHYL)AMINO]ACETYL]AMINO]-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, (4S,4AS,5AR,12AS)-;(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-9-[(tert-butylamino)acetamido]-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-carboxamide;tigecycline;TIGECYCLINE GLYCYLCYCLINE;(4S,4As,5aR,12as)-4,7-Bis(dimethylamino)-9-{(tert-butylamino)acetamido}-3,10,12,12a-octahydrotetracen-2-carboxamide;(4S,4aS,5aR,12aS)-4,7-Bis(dimethylamino)-9-[(tert-butylamino)acetamido]-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-carboxamide;2-NAPHTHACENECARBOXAMIDE;TIGECYCLINE POWDER |
| CAS: | 220620-09-7 |
| MF: | C29H39N5O8 |
| MW: | 585.65 |
| EINECS: | |
| Product Categories: | Antibacterial;API;Amines;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol File: | 220620-09-7.mol |
|
|
|
Details
| Tigecycline Chemical Properties |
| mp | 164-166°C |
| storage temp. | Amber Vial, -20°C Freezer |
| CAS DataBase Reference | 220620-09-7(CAS DataBase Reference) |
| Safety Information |
| Tigecycline Usage And Synthesis |
| Gansu ammonia acyl ring element class of antibiotics |
Tigecycline is also known as the 9- tert butyl glycyl amino minocycline or Ding Gan minocycline, and is a new broad-spectrum activity of intravenous injection with antibiotics, belonging to 9- tert butyl glycyl amino minocycline derivatives, is the first glycocholic acid antibiotics, in order to solve the resistance of early achromycin. In June, 1995, it is approved by the United States FDA. Although its structure is similar to minocycline, but after the molecular structure changes, not only its antibacterial activity is greatly improved, and compared with other tetracycline drugs, bacteria is not easy to produce drug resistance, Staphylococcus aureus, which is resistance to methicillin resistant , also has activity the resistance. The prime mechanism of tigecycline are similar to tetracycline antibiotics, both combine with bacterial 30S ribosomal, stop entering the transfer RNA, make the amino acid uncombined into peptide chains, eventually blocking protein synthesis of bacteria, limiting bacterial growth. But the binding capacity of tigecycline with ribosome is 5 times of other tetracyclines drugs. That showed that the resistance to bacterial was stonger than other tetracyclines drugs. Antibacterial spectrum of tetracyclines including gram positive bacteria, gram negative bacteria and anaerobic bacteria. The vitro experiments and clinical trials show that tetracyclines are sensitive to the part of the aerobic gram negative bacteria (such as Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca and Klebsiella pneumoniae, Bowman Acinetobacter, Aeromonas water vapor, G freundii, Enterobacter aerogenes, Pasteurella multocida, Serratia marcescens and stenotrophomonas maltophilia,etc.). Pseudomonas aeruginosa bacteria is resistance to tigecycline. The above information is edited by the Chemicalbook Hanya. |
| Indication |
Tigecycline can be the selection, after failure treatment of multi drug resistant bacteriaof first-line drugs, but also for penicillin allergy or not tolerate other drug treatment of patients with new treatment options. It applicates to 18 years old and above the age of 18 patients with complicated skin and skin structure infections or complicated intra-abdominal infection with treatment, including complicated appendicitis, burn infection, intra-abdominal abscess, deep soft tissue infection and ulcer infection. |
| Adverse reaction | In a clinical trial, the most common adverse events caused by tigecycline were nausea and vomiting, and its occurrence time in the treatment of head 1 ~ 2 days, the degree is moderate. In positive drug controlled clinical trials, complicated skin and skin structure infections in patients with treatment of tigecycline, the nausea and vomiting incidence were 35% and 20%, the use of vancomycin aztreonam treatment, nausea and vomiting were 8.9% and 4.2%. Complicated intra-abdominal infection in patients with tegafur prostacyclin treatment, the nausea and vomiting incidence were 25.3% and 19.5%. Application of vancomycin aztreonam treatment, nausea and vomiting were 20.5% and 15.3%. |
| Chemical Properties | Orange Solid |
| Usage | antineoplastic |
| Usage | Tigecycline is a semi-synthetic tetracycline prepared by the introduction of a tert-butylaminoacetamido group into a previously unexplored and un-substituted region of existing tetracyclines. Like other tetracyclines, tigecycline acts by reversibly binding to the 30S ribosomal subunit and inhibits protein translation by blocking entry of aminoacyl-tRNA into the ribosome A site. The enhanced activity can be attributed to stronger binding affinity, thus minimising the impact of existing mechanisms of resistance. Tigecycline is regarded as the first of a new class of glycylcyline antibiotics. Critical comparison to the tetracycline class appears to be lacking in the literature. |
| Usage | A broad spectrum glycylcycline antibiotic |
| Usage | A glycylcycline antibiotic, used to treat infection by drug resistant bacteria such as Staphylococcus aureus (Staph aureus) and Acinetobacter baumannii. |